The PsychOsis and Diabetes Service Model (PODS) Population Profile Study.
NCT05456984 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 125
Last updated 2022-12-13
Summary
People with severe mental illness (SMI), defined as psychotic and bipolar disorders, die 17-20 years earlier than the general population, the most common cause of death being cardiovascular diseases (CVD). The major contributor to CVD mortality in SMI is the increased prevalence of type 2 diabetes (T2D) compared to the general population. T2D is a paradigm of a single condition that progresses to multiple conditions. T2D requires annual reviews of 9 diabetes care processes and for patients to adopt multiple self-care tasks to prevent diabetes complications. The 9 diabetes care processes include: 3-6 monthly blood glucose measurement (HbA1c) with appropriate targets; blood pressure measurements and targets depending on diabetes complication status; annual blood cholesterol measurement; kidney function testing with urinary albumin; kidney function testing with serum creatinine; weight check; smoking status; diabetes annual eye screening; and annual foot examination.
In the National Diabetes Audit 2016-17, people with SMI and T2D were 10% less likely to take up all 9 diabetes care processes and have worse glycaemic control as a result. Therefore the aim of this study is to determine who is receiving these care processes and to develop new care pathways/interventions that support this population.
This project is a cross-sectional study and will take place in Lambeth south London, an area with high prevalence of SMI, and therefore T2D, and deprivation. W aim to profile the entire population of people with SMI and T2D within the Hills Brook and Dales and StockWELL Primary Care Networks. The investigators will access the participants medical records and record details of their latest physical health assessment and ask them to complete 7 validated questionnaires and brief informal interview either face to face in their GP surgery or over the phone. This project has been funded by the Burdett Trust for Nursing.
Conditions
- Type2Diabetes
- Severe Mental Disorder
Sponsors & Collaborators
-
Burdett Trust for Nursing
collaborator OTHER - lead OTHER
Principal Investigators
-
Kirsty Winkley · King's College London University
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-05-03
- Primary Completion
- 2022-08-10
- Completion
- 2022-08-10
Countries
- United Kingdom
Study Locations
More Related Trials
-
Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications
NCT00344500 ·Status: COMPLETED ·Phase: NA
-
Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness
NCT02029989 ·Status: COMPLETED ·Phase: NA
-
Reducing Weight and Diabetes Risk in an Underserved Population (STRIDE)
NCT00790517 ·Status: COMPLETED ·Phase: PHASE2
-
Determining Metabolic Effects of Valproate and Antipsychotic Therapy
NCT00167934 ·Status: COMPLETED ·Phase: NA
-
Antipsychotics and Blood Vessel Function
NCT00585273 ·Status: COMPLETED
-
Effects of Antipsychotics on Brain Insulin Action in Females
NCT06251635 ·Status: RECRUITING ·Phase: NA
-
Glucose and Lipid Metabolism on Antipsychotic Medication
NCT00515723 ·Status: COMPLETED ·Phase: NA
-
MetSense Pilot and Feasibility
NCT07264062 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications - 2
NCT01052714 ·Status: COMPLETED ·Phase: NA
-
Alleviating the Metabolic Side Effects of Antipsychotic Medications
NCT01567124 ·Status: WITHDRAWN ·Phase: PHASE4
-
Antipsychotics and Risk of Hyperglycemic Emergencies
NCT02582736 ·Status: COMPLETED
-
Diabetes Prevention Program in Schizophrenia [DPPS]
NCT00182494 ·Status: UNKNOWN ·Phase: PHASE4
-
Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia
NCT05748990 ·Status: RECRUITING ·Phase: NA
-
The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With Obesity
NCT06331286 ·Status: UNKNOWN ·Phase: NA
-
Precision Subclassification of Mental Health in Diabetes: Digital Twins for Precision Mental Health to Track Subgroups
NCT07212075 ·Status: RECRUITING
-
Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity
NCT05333003 ·Status: RECRUITING ·Phase: NA
-
Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs
NCT02515773 ·Status: COMPLETED ·Phase: PHASE4
-
Metabolic Side-effects for Second-generation Antipsychotics
NCT01280396 ·Status: COMPLETED
-
Weight Management Program for Patients With First Episode Psychosis
NCT05207982 ·Status: COMPLETED ·Phase: PHASE1
-
Glucagon-like Peptide 1 (GLP1) Receptor Agonists and Mental Health
NCT05492305 ·Status: UNKNOWN
-
Investigation Of How PD 0332334 And Metformin Are Eliminated From The Body When They Are Administered At The Same Time
NCT00809536 ·Status: TERMINATED ·Phase: PHASE1
-
Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT05744479 ·Status: RECRUITING ·Phase: PHASE4
-
Treating Insulin Resistance as a Strategy to Improve Outcome in Refractory Bipolar Disorder
NCT02519543 ·Status: COMPLETED ·Phase: PHASE3
-
Metabolic Syndrome in Patients With First-episode Schizophrenia
NCT00957294 ·Status: COMPLETED
-
DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics
NCT00752960 ·Status: UNKNOWN